Century Therapeutics, Inc. (IPSC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.59M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -116.99M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $5.59M | $-116.99M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $5.86M | $-115.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $109.16M | $6.84M | $-17.27M | (m) | (m) | 6.27% | (m) | (m) |
| 2025-09-30 | (m) | $113.34M | $8.20M | $-33.90M | (m) | (m) | 7.24% | (m) | (m) |
| 2025-06-30 | (m) | $114.13M | $10.63M | $-32.56M | (m) | (m) | 9.31% | (m) | (m) |
| 2025-03-31 | (m) | $114.90M | $11.91M | $-32.65M | (m) | (m) | 10.36% | (m) | (m) |
| 2024-12-31 | (m) | $6.59M | $12.69M | $-138.14M | (m) | (m) | 192.56% | (m) | (m) |
| 2024-09-30 | (m) | $2.68M | $13.59M | $-144.62M | (m) | (m) | 506.33% | (m) | (m) |
| 2024-06-30 | (m) | $2.04M | $14.25M | $-145.46M | (m) | (m) | 698.19% | (m) | (m) |
| 2024-03-31 | (m) | $1.37M | $14.03M | $-145.77M | (m) | (m) | 1024.23% | (m) | (m) |
| 2023-12-31 | (m) | $2.23M | $14.62M | $-146.55M | $540.00K | (m) | 654.23% | -271.38× | Reported |
| 2023-09-30 | (m) | $2.49M | $13.79M | $-136.09M | $927.00K | (m) | 554.34% | -146.81× | Reported |
| 2023-06-30 | (m) | $4.56M | $12.60M | $-132.20M | $1.30M | (m) | 276.07% | -101.69× | Reported |
| 2023-03-31 | (m) | $5.86M | $12.09M | $-128.48M | $1.49M | (m) | 206.21% | -85.99× | Reported |
| 2022-12-31 | (m) | $5.20M | $10.67M | $-133.83M | $1.40M | (m) | 205.21% | -95.32× | Reported |
| 2022-09-30 | (m) | (m) | $9.57M | $-128.50M | $1.34M | (m) | (m) | -96.04× | Reported |
| 2022-06-30 | (m) | (m) | $8.01M | $-122.59M | $1.29M | (m) | (m) | -95.25× | Reported |
| 2022-03-31 | (m) | (m) | $6.95M | $-114.26M | $1.27M | (m) | (m) | -89.61× | Reported |
| 2021-12-31 | $75.65M | (m) | $4.66M | $-94.88M | $1.27M | (m) | (m) | -74.42× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $39.68M | (m) | $876.00K | $-53.90M | $381.00K | (m) | (m) | -141.46× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |